SCHEMBL2773055

SCHEMBL2773055

CN(CCNC(=O)NCc1ccccc1)CCNc1cc(N2CCCC2)nc(N2CCCC2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SENP6 Q9GZR1 4/20 0.49
MAPT P10636 3/20 0.49
SENP7 Q9BQF6 3/20 0.49
APAF1 O14727 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
GBA1 P04062 1/20 0.46
HRH4 Q9H3N8 3/20 0.42
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.42
CASP1 P29466 3/20 0.42
CASP5 P51878 3/20 0.42
HRH1 P35367 2/20 0.42
DRD2 P14416 1/20 0.42
DRD3 P35462 1/20 0.42
ACHE P22303 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2774055 0.86 MAPT (0.43) SENP6MAPTSENP7APAF1SMN1; SMN2
SCHEMBL2772122 0.86 HPGD (0.44) SENP6MAPTSENP7APAF1SMN1; SMN2
SCHEMBL2791335 0.83 MAPT (0.44) SENP6MAPTSENP7APAF1SMN1; SMN2
SCHEMBL2789360 0.83 APAF1 (0.52) SENP6MAPTSENP7APAF1SMN1; SMN2
SCHEMBL2772821 0.82 SENP6 (0.48) SENP6MAPTSENP7APAF1SMN1; SMN2
SCHEMBL3475816 0.82 HRH4 (0.46) SENP6MAPTSENP7APAF1SMN1; SMN2
SCHEMBL2772654 0.81 KMT2A (0.41) SENP6MAPTSENP7APAF1SMN1; SMN2
SCHEMBL2772121 0.81 MAPT (0.40) SENP6MAPTSENP7APAF1SMN1; SMN2
SCHEMBL2787353 0.81 CNR1 (0.46) MAPTSMN1; SMN2GBA1ALDH1A1MEN1
SCHEMBL2771563 0.80 MAPT (0.42) SENP6MAPTSENP7APAF1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137275-A1 TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE IPSEN PHARMA S.A.S. (FR) 2010-06-03 US claimed
US-20100137275-A1 TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE IPSEN PHARMA S.A.S. (FR) 2010-06-03 US disclosed
EP-2152675-A1 TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE IPSEN PHARMA S.A.S. (FR) 2010-02-17 EP disclosed
WO-2008152223-A1 TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE IPSEN PHARMA S.A.S. (FR) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137275-A1 TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE CDC25A, CDC25B, CDC25C SENP6 1145/4885MAPT 4555/4885SENP7 1810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.